The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer

被引：1

作者：

Hu, Zongfeng ^{[1
]}

Liu, Wenqi ^{[1
]}

Liu, Jiajia ^{[2
]}

Zhou, Hua ^{[2
]}

Sun, Chunyang ^{[2
]}

Tian, Chao ^{[2
]}

Guo, Xiaona ^{[1
]}

Zhu, Chengyang ^{[1
]}

Shao, Mingxia ^{[1
]}

Wang, Shengrun ^{[1
]}

Wei, Lijun ^{[1
]}

Liu, Min ^{[1
]}

Li, Shuzhen ^{[1
]}

Wang, Jinyu ^{[1
]}

Xu, Haitian ^{[1
]}

Zhu, Wei ^{[1
]}

Li, Xiaopeng ^{[1
,2
]}

Li, Jingfeng ^{[1
]}

机构：

[1] Yantai Univ, Sch Pharm, Yantai 264005, Shandong, Peoples R China

[2] Beijing WellGene Co Ltd, Beijing 100085, Peoples R China

来源：

ANTIVIRAL RESEARCH | 2024年 / 232卷

基金：

中国国家自然科学基金;

关键词：

Oncolytic virus; HSV-1; CRISPR/Cas9; HPV16; Cervical cancer; IN-VIVO; CELLS; REPLICATION; CISPLATIN; THERAPY; GENOME; E6;

D O I：

10.1016/j.antiviral.2024.106035

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cervical cancer, often driven by high-risk human papillomavirus (HPV) infections such as HPV16 or HPV18, remains a leading cause of cancer-related deaths. HPV16, found in about 90% of cervical cancer patients, harbors key oncogenic related genes (E6, E7, E2, E5) and an upstream regulatory region (URR) that contribute to cancer progression. This study introduces a novel approach using a recombinant oncolytic herpes simplex virus type 1 (HSV-1) named SONC103, armed with a CRISPR/Cas9 gene editing system. The aim was to target and disrupt integrated HPV16 genes in cervical cancer cells. Results demonstrated SONC103's capability to specifically and effectively knock down HPV16 oncogenes, thereby reducing cell proliferation and promoting apoptosis. Analyses further revealed loss of HPV16 DNA probes in infected cells' chromosomes, significant regulation of cellular processes related to tumor apoptosis, and downregulation of E6/E7 oncoproteins while increasing tumor suppressor proteins P53 and pRB. Notably, SONC103 exhibited substantial inhibition of tumor growth in a murine xenograft cervical cancer model. This study showcases the potential of the recombinant oncolytic HSV-1 virus (SONC103) in combating HPV16-positive cervical cancer by targeting oncogenes and facilitating oncolysis.

引用

页数：10

共 36 条

[1] The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line [J].

Adey, Andrew ;

Burton, Joshua N. ;

Kitzman, Jacob O. ;

Hiatt, Joseph B. ;

Lewis, Alexandra P. ;

Martin, Beth K. ;

Qiu, Ruolan ;

Lee, Choli ;

Shendure, Jay .

NATURE, 2013, 500 (7461) :207-+

[2] Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus [J].

Aref, Sarah ;

Castleton, Anna Z. ;

Bailey, Katharine ;

Burt, Richard ;

Dey, Aditi ;

Leongamornlert, Daniel ;

Mitchell, Rachel J. ;

Okasha, Dina ;

Fielding, Adele K. .

MOLECULAR THERAPY, 2020, 28 (04) :1043-1055

[3] Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation [J].

Blank, SV ;

Rubin, SC ;

Coukos, G ;

Amin, KM ;

Albelda, SM ;

Molnar-Kimber, KL .

HUMAN GENE THERAPY, 2002, 13 (05) :627-639

[4] Characterization of HPV integration, viral gene expression and E6E7 alternative transcripts by RNA-Seq: A descriptive study in invasive cervical cancer [J].

Brant, Ayslan C. ;

Menezes, Albert N. ;

Felix, Shayany P. ;

de Almeida, Liz M. ;

Sammeth, Michael ;

Moreira, Miguel A. M. .

GENOMICS, 2019, 111 (06) :1853-1861

[5] SEQUENCE DUPLICATION AND INTERNAL DELETION IN THE INTEGRATED HUMAN PAPILLOMAVIRUS TYPE-16 GENOME CLONED FROM A CERVICAL-CARCINOMA [J].

CHOO, KB ;

LEE, HH ;

PAN, CC ;

WU, SM ;

LIEW, LN ;

CHEUNG, WF ;

HAN, SH .

JOURNAL OF VIROLOGY, 1988, 62 (05) :1659-1666

[6] HnRNP D activates production of HPV16 E1 and E6 mRNAs by promoting intron retention [J].

Cui, Xiaoxu ;

Hao, Chengyu ;

Gong, Lijing ;

Kajitani, Naoko ;

Schwartz, Stefan .

NUCLEIC ACIDS RESEARCH, 2022, 50 (05) :2782-2806

[7] Worldwide burden of cancer attributable to HPV by site, country and HPV type [J].

de Martel, Catherine ;

Plummer, Martyn ;

Vignat, Jerome ;

Franceschi, Silvia .

INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (04) :664-670

[8] The new frontier of genome engineering with CRISPR-Cas9 [J].

Doudna, Jennifer A. ;

Charpentier, Emmanuelle .

SCIENCE, 2014, 346 (6213) :1077-+

[9] Cervical Cancer Immunotherapy: Facts and Hopes [J].

Ferrall, Louise ;

Lin, Ken Y. ;

Roden, Richard B. S. ;

Hung, Chien-Fu ;

Wu, T. -C. .

CLINICAL CANCER RESEARCH, 2021, 27 (18) :4953-4973

[10] Oncolytic virus therapy: A new era of cancer treatment at dawn [J].

Fukuhara, Hiroshi ;

Ino, Yasushi ;

Todo, Tomoki .

CANCER SCIENCE, 2016, 107 (10) :1373-1379

← 1 2 3 4 →